Knight adds to debt funding of VC-backed Antibe Therapeutics
Antibe Therapeutics Inc (TSX-V: ATE) has announced a second closing of a convertible debentures financing, which has generated total proceeds of $2.6 million. Knight Therapeutics Inc (TSX: GUD) invested in the deal's second tranche, adding to an earlier investment by Bloom Burton Healthcare Lending Trust. Knight also entered into a license and distribution agreement with Antibe, a healthcare company focused on treatments for pain and inflammation. Toronto-based Antibe, which recently acquired a majority interest in Citagenix Inc, is a portfolio investment of Canadian venture capital firms AVAC and Hero Ventures.
16 November 2015•5 mins read
